- Home
- RNAZ vs BIAF Comparison
RNAZ vs BIAF Comparison
Compare RNAZ & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- BIAF
- Stock Information
- Founded
- RNAZ 2016
- BIAF 2014
- Country
- RNAZ United States
- BIAF United States
- Employees
- RNAZ N/A
- BIAF N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RNAZ Health Care
- BIAF Health Care
- Exchange
- RNAZ Nasdaq
- BIAF Nasdaq
- Market Cap
- RNAZ 8.7M
- BIAF 7.6M
- IPO Year
- RNAZ 2021
- BIAF 2022
- Fundamental
- Price
- RNAZ $14.80
- BIAF $3.24
- Analyst Decision
- RNAZ Strong Buy
- BIAF Hold
- Analyst Count
- RNAZ 1
- BIAF 1
- Target Price
- RNAZ $280.00
- BIAF N/A
- AVG Volume (30 Days)
- RNAZ 387.0K
- BIAF 7.6M
- Earning Date
- RNAZ 11-13-2025
- BIAF 11-13-2025
- Dividend Yield
- RNAZ N/A
- BIAF N/A
- EPS Growth
- RNAZ N/A
- BIAF N/A
- EPS
- RNAZ N/A
- BIAF N/A
- Revenue
- RNAZ N/A
- BIAF $7,681,059.00
- Revenue This Year
- RNAZ N/A
- BIAF N/A
- Revenue Next Year
- RNAZ N/A
- BIAF $20.04
- P/E Ratio
- RNAZ N/A
- BIAF N/A
- Revenue Growth
- RNAZ N/A
- BIAF 4.99
- 52 Week Low
- RNAZ $6.15
- BIAF $2.34
- 52 Week High
- RNAZ $739.20
- BIAF $67.12
- Technical
- Relative Strength Index (RSI)
- RNAZ 84.37
- BIAF 53.34
- Support Level
- RNAZ $10.32
- BIAF $2.36
- Resistance Level
- RNAZ $12.28
- BIAF $7.29
- Average True Range (ATR)
- RNAZ 0.87
- BIAF 0.63
- MACD
- RNAZ 0.57
- BIAF -0.30
- Stochastic Oscillator
- RNAZ 91.34
- BIAF 23.73
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.